COMMUNIQUÉS West-GlobeNewswire
-
Axiom Biosciences Reports Positive Phase 1 Results for Investigational Stem Cell Therapy in Newborns with Severe Brain Injury
14/07/2026 -
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
14/07/2026 -
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
14/07/2026 -
Foundation for Sarcoidosis Research Announces 13 Inaugural Sites for Groundbreaking FSR Clinical Data Registry
14/07/2026 -
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
14/07/2026 -
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
14/07/2026 -
ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
14/07/2026 -
Transactions in connection with share buy-back program
14/07/2026 -
Nucleome Therapeutics strengthens global IP portfolio with US patent for core MCC Technology
14/07/2026 -
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
14/07/2026 -
Erasca Announces Pricing of Upsized Public Offering of Common Stock
14/07/2026 -
Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis
14/07/2026 -
Capilea México Releases Overview of Hair Transplant Success Rates and FUE Technology in Mexico
14/07/2026 -
Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
14/07/2026 -
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
14/07/2026 -
Tevogen Bio Announces 2026 Annual Meeting of Stockholders
14/07/2026 -
Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance
13/07/2026 -
Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi
13/07/2026 -
Tilray Brands to Announce Fourth Quarter and Fiscal Year 2026 Financial Results on July 28, 2026
13/07/2026
Pages